Companies / MYX

MAYNE PHARMA GROUP LIMITED

ASX:MYXPharmaceuticals, Biotechnology & Life Sciences
81.2M shares on issueASX (delayed) · as of 28 July 2026$2.63price · delayed$220.2Mmarket cap · indicative
A
Dilution grade

No issuance filings since 2024; no dilution pressure signals in current disclosures

Cash runwayno data — not a quarterly (4C/5B) cash filer
Share-count growth (24m)0.0%no issuance filings since 2024
Raise cadence (24m)0 cash raises
Options & rights overhang0.0% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

MAYNE PHARMA GROUP LIMITED has not lodged any share-issuance (Appendix 2A) filings in the review window and therefore a share-count series is not available. There were no capital raises in the 24-month window. Options and rights overhang data are not provided. The company does not have a current quarterly cash report on record, so no cash balance or funding-runway figure is disclosed. There are no proposed securities issues (Appendix 3B) pending. The company listed in June 2007 is noted but has not lodged new Appendix 2A filings since January 2024.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
0.0%
Max option dilution
0.0%
ITM option dilution
0
Raises · last 12 months
—
Cash cover · not a quarterly filer

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 81.2M per ASX (delayed) (28 July 2026).
80.9M81.2M81.6MDec 24Sept 25July 26

Cash runway

Not a quarterly cash filer. This company does not lodge Appendix 4C/5B quarterly cash reports, so cash runway does not apply.

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
6 July 20263G · unquotedORDINARY FULLY PAID81.2MAppendix 3G
6 July 20263G · unquotedORDINARY FULLY PAID81.2MAppendix 3G
6 July 20263G · unquotedMYX : ORDINARY FULLY PAID81.2MAppendix 3G
6 July 20263G · unquotedMYX : ORDINARY FULLY PAID81.2MAppendix 3G
4 May 20263H · cancellationMYX : ORDINARY FULLY PAID81.2MAppendix 3H
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

No equity raises in the last 24 months.
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

No options or rights over unissued shares on record.

Director dealings

DateDirectorTypeSharesOptionsValueSource
16 Dec 2025Shawn Patrick O'BrienSell326k—$401k3Y notice
28 Feb 2022Bruce RobinsonSell———3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

16 July 2026Mayne Pharma appoints new Chief Financial Officer
6 July 2026Notification regarding unquoted securities - MYX
6 July 2026Notification regarding unquoted securities - MYX
6 July 2026Notification regarding unquoted securities - MYX
6 July 2026Notification regarding unquoted securities - MYX
30 June 2026Initial Director's Interest Notice
25 June 2026Mayne Pharma appoints new Non-Executive Director
25 June 2026Change in substantial holding
18 June 2026Change in substantial holding
5 June 2026Final Director's Interest Notice
5 June 2026$PMayne Pharma receives $14.4m for legal costs from Cosette
4 June 2026MYX Jefferies Global Healthcare Conference Presentation
31 May 2026New DistributeRx partnership with Resilia Pharmaceuticals
26 May 2026Mayne Pharma to present at Jefferies Healthcare Conference
22 May 2026$PCourt awards MYX $13.27m for legal costs from Cosette
17 May 2026Mayne Pharma announces expansion of Adelaide Apothecary
6 May 2026Mayne Pharma 3Q investor presentation
4 May 2026Notification of cessation of securities - MYX
29 Apr 2026Further details re equity instruments to be issued to CEO
28 Apr 2026$PMayne Pharma reports unaudited 3Q FY26 results

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.